Introduction {#Sec1}
============

Head lice (*Pediculus humanus capitis*) are hematophagous ectoparasites which live on the human scalp. They are very contagious and typically spread via close contact with infested individuals. Head lice are common and widely spread, with highly diverging prevalence values \[[@CR1], [@CR2]\].

Because of increasing resistance and safety issues \[[@CR3], [@CR4]\], the use of insecticides (e.g., pyrethroids) as first-line agents against head lice has been largely surpassed by physically acting, substance-based medical devices that typically contain silicones and/or mineral oils. The physical mode of action of these devices is widely accepted and relies on suffocation of the ectoparasites by blocking their respiratory channel, hereby impairing water and gas exchange. Mineral oils are also able to disrupt the epicuticular wax layer of head lice \[[@CR5]--[@CR8]\].

Such agents have a lipophilic character, and especially high-molecular-weight silicones can accumulate on the hair, making them difficult to wash out and therefore turning the hair greasy \[[@CR9]\]. These negative properties have led researchers to search for alternative, physically active compounds that combine efficacy and optimal user convenience in terms of treatment period and with the lack of negative effects on hair quality. Different screening efforts have resulted in the identification of a group of synthesized, silylated polyols, which show the most interesting properties with respect to adulticidal and ovicidal activity (100% mortality). Furthermore, in contrast to the high-molecular-weight silicones, short silylated polyols have a very low viscosity, allowing easy dispersion in viscous aqueous formulations. From an esthetical point of view, these molecules are promising as they do not leave residue on the hair and do not have a negative impact on hair quality in general.

The clinical trial described here was designed and implemented to compare the efficacy, safety, and cosmetic effects of an aqueous dispersion of a silylated polyol (Prosil) versus a first-line, prescription-free treatment in the USA: RID shampoo (pyrethrum-based). We also performed a blinded, cross-over consumer study to further evaluate the esthetic effects of the test product versus a silicone-based product (4% dimethicone).

Methods {#Sec2}
=======

Clinical Study Set-Up {#Sec3}
---------------------

This randomized, controlled, investigator-blinded, comparative study was approved by the Schulman IRB Ethics Committee (Cincinnati, OH, USA) on 16 January 2018. The trial was conducted according to the international guideline for clinical trials with pediculicides \[[@CR10]\], in accordance with Good Clinical Practice and with the principles of the Declaration of Helsinki 2013. This study was registered at ClinicalTrials.gov (NCT03617926).

The entire clinical study took place at two clinical trial sites in Florida (USA) that are specialized in treating people infested with head lice (site 1: Lice Source Services, Plantation, FL; site 2: Lice Cleanique, Miami, FL). Recruitment was performed by trained personnel and continued from 7 March 2018 (first visit of first patient) to 30th June 2018 (last visit of last patient). Patients were recruited among infested subjects who visited one of either clinic for a head lice treatment.

Inclusion and Exclusion Criteria {#Sec4}
--------------------------------

Inclusion and exclusion criteria were identical to those used in the study of Wolf et al. \[[@CR11]\]. Briefly, patients (\> 2 years of age; male/female) were included after head lice infestation was confirmed. Full scalp and hair diagnoses were performed by experienced clinical staff using a plastic head lice comb. First, the hair was detangled into three sections, and every section was combed six times, beginning at the scalp and ending at the hair tips. Head lice caught by the comb were left in the hair to avoid bias. The severity of the head lice infestation was classified as follows: not relevant (\< 5 lice and/or nymphs), mild (5--9 lice and/or nymphs), moderate (10--24 lice and/or nymphs), and severe (≥ 25 lice and/or nymphs).

Only patients with a mild, moderate, or severe infestation, with at least five apparently live nits (based on location and visual appearance), and a good general condition were included in the study. Exclusion criteria were: sensitivity towards ingredients; use of a pediculicide 1 month prior to and during the study; use of topical drugs or medication which may interfere with study outcome; scalp disorders; pregnancy or lactation; participation in another clinical trial (also taking into account a period of 4 weeks before study start); being affiliated to the sponsor or investigator site personnel; and non-compliance with the protocol.

Informed Consent, Randomization, and Baseline Data {#Sec5}
--------------------------------------------------

During recruitment, the clinical staff provided detailed information on study procedures and objectives. Following written consent by the participant (or his/her legal representative), each subject was randomly allocated into one of two groups. Baseline demographic and clinical data were collected. Prior to the study, a randomization list was built by an external statistician using SAS software (version 9.4; SAS Institute, Cary, NC, USA). For this purpose, block randomization with a variable block size (2--8) was used. All patients confirmed their availability for the 10-day duration of the study.

Blinding {#Sec6}
--------

Because of differences in product characteristics (color, odor, composition...), a double-blinded study was not possible. Therefore, treatments were provided by unblinded study staff, whereas consequent assessments were performed by blinded study staff (not involved in the treatments) to avoid any product bias.

Study Products, Dosage, and Administration {#Sec7}
------------------------------------------

Both products were applied according to the respective instructions for use. The test product (medical device) and corresponding lice comb were supplied by Oystershell (Merelbeke, Belgium). The lotion is provided as a dual chamber packaging system. Briefly, the cap contains the concentrated silylated polyol (Prosil), which is dissolved in a lipophilic vehicle. The 100-ml plastic bottle contains the water diluent (supplemented with preservatives, perfume, and a viscosity modifier). Prior to use, the cap is activated by pushing, hereby releasing the Prosil into the water phase. Next, the product is shaken thoroughly and immediately applied onto dry hair until the hair is fully saturated. After 15 (+ 2) min, the hair is rinsed with warm water and a commercial mild shampoo (Johnson's baby shampoo; Johnson & Johnson, New Brunswick, NJ, USA).

The reference product, namely RID shampoo, is commercially available in the USA. It contains pyrethrum extract (equivalent to 0.33% pyrethrins) and piperonyl butoxide (4%), with the latter serving as activity booster. Pyrethrum is extracted from flower heads of *Chrysanthemum cinerariifolium* and contains pyrethrins, cinerins, and jasmolins. The extract has neurotoxic effects and kills insects, including head lice, by acting on their central nerve system (disruption of muscle neurotransmission) \[[@CR3], [@CR12]\]. The clinical trial centers purchased RID shampoo from stores as 118-ml glass bottles, supplemented with a lice comb.

Depending on the length of the hair, the following volumes were applied to the hair (according to the instructions for use): 60 ml (short hair), 90 ml (shoulder length-hair), and complete bottle (mid-back hair), respectively. The product was applied evenly in dry hair over its full length, with special attention paid to the hair and scalp. After 10 (+ 2) min, warm water was applied, and the product was rinsed out thoroughly.

Patients received two treatments, a first application at visit 1 (day 0) and a second at visit 3 (day 7), according to the instructions for use of both products.

Efficacy Evaluation {#Sec8}
-------------------

Infestation degree in both treatment groups was diagnosed using a plastic head lice comb. Assessments were made at the following time points: day 0 (visit 1), 24 h post treatment (visit 2), day 7 post treatment (prior to second treatment; visit 3), and day 10 post treatment(visit 4).

The primary objective of this study was to demonstrate that the cure rate of the test product surpassed 70% at day 10. The cure rate is the proportion of patients without any living lice, corrected for re-infestation and was defined as (1) no adult lice or third-stage nymphs present following the first treatment, and (2) no more than two adult lice or third-stage nymphs found by combing on day 10 \[[@CR13]\].

The secondary efficacy objectives were to show (1) that the cure rate at the end of day 10 (corrected for re-infestation) for the reference product surpassed 70%, and (2) that the test product had a cure rate superior to that of the reference product. In the case that superiority could not be shown, the secondary efficacy objectives were to demonstrate that the test product was non-inferior to the reference product, using a non-inferiority margin of 7.5%. More detailed information is provided in the [Statistical Analyses](#Sec14){ref-type="sec"} section.

Sample Size Calculation {#Sec9}
-----------------------

Sample size calculation relied on previous unpublished and published clinical data \[[@CR11]\]. A pre-defined limit of 70% was chosen, based on the highest cure rate reported to date, from a clinical trial with a pyrethroid-based pediculicide \[[@CR14]\]. This limit was assumed to be the minimal acceptable cure rate. A sample size of 30 was needed for a one-sample Chi-square test, comparing a cure rate of 95% with a fixed limit of 70% (two-sided test; alpha level of 0.05; power 80%). For the control group, an identical sample size was used.

Assuming a 10% drop-out and a 5% re-infestation rate, the sample size was multiplied by 1.1 × 1.05, resulting in 35 cases per group (*n* = 70 in total).

Safety Evaluation {#Sec10}
-----------------

Assessment of safety, tolerability, and acceptance of both products were some of the secondary objectives. Such assessments were performed before and after the first (day 0) and second treatment (day 7), respectively. A final examination was done at study end (day 10) to assess local tolerability, as reflected by the presence of burning, pruritus, and paresthesia. Study staff evaluated skin condition (secondary infection, skin redness, excoriation) and ocular irritation on days 0, 1, 7, and 10, respectively. Global tolerability was evaluated by the clinical staff at study end.

Esthetic Questionnaire {#Sec11}
----------------------

Following application of the first and second treatment, an aesthetic questionnaire was completed by the subjects on days 0 and 7, respectively. The questions related to dryness, shininess, greasiness, and volume of the hair; feeling of the hair and scalp; and the conditioning effect of the treatment. The following scores were assigned: (a) strongly agree, (b) agree, (c) disagree, and (d) strongly disagree.

Consumer Study {#Sec12}
--------------

The blinded, cross-over study was designed and implemented by VG Sensory (Deinze, Belgium), a firm which is specialized in conducting consumer tests and evaluating sensory properties of cosmetics, food products, among others. The study started on 9 August 2018 and finished on 25 September 2018. Subjects (*n* = 100) were recruited from a database of people with home experience in the use of head lice products. In this study, the test product was compared to a commercially available 4% dimethicone lotion. People were instructed to use the product according to the respective leaflet. A commercially available mild shampoo was used to wash out the product (same for both treatments). At study start, 50 subjects started with one test product and the remaining 50 with the other. Following treatment, a "wash-out" period of 14 days had to be respected before the participants started on the other treatment. Different parameters were recorded in a diary: time required to wash out the product; the number of washings required to restore hair characteristics; and the volume of shampoo used. All subjects completed a questionnaire to score the esthetic aspects of the hair, including greasiness, shininess, feel, and of the scalp, among others.

In vitro Adulticidal Tests and Microscopical Analyses {#Sec13}
-----------------------------------------------------

Living head lice were collected from a school in the direct environment of Oystershell Laboratories and immediately used in an in vitro adulticidal test. Briefly, all stages of viable head lice (*n* = 10) were transferred to a self-made "arena", which was an enclosed circle of nylon gauze. Next, head lice were treated with 2 ml of the test product, namely, 4% dimethicone lotion (positive control), or with 2 ml tepid water (negative control) for 15 min. Following incubation, lice were rinsed with a 5% dilution of a commercial shampoo and water. Survival was assessed at distinct time points for a period of up to 3 h. Treated lice (all products) were then transferred to the LIMID laboratory (University of Antwerp, Belgium) for microscopical analysis to evaluate penetration of test product in the respiratory tract. This method was based on experiments performed by Richling \[[@CR15]\]. Imaging of the lice was performed with a Zeiss Stemi SV11 stereomicroscope (Carl Zeis NV, Zaventem, Belgium), equipped with an Olympus DP70 CCD Camera (Olympus, Antwerp, Belgium).

Statistical Analyses {#Sec14}
--------------------

Clinical trial data were analyzed by an independent statistician according to the International Conference on Harmonization (ICH) E9 Note for Guidance on Statistical Principles for Clinical Trials \[[@CR16]\].

Efficacy analyses were performed on the intention-to-treat (ITT) population. The latter included all subjects who were recruited and randomized in the study, with baseline values of the primary endpoint, and at least one follow-up visit for the efficacy parameters. A 5% level of significance level was applied for analyses.

The cure rate (*p*) corresponds to the proportion of patients who were cured at day 10 among all patients that received any treatment at day 0. The aim of this study was to establish superiority for the cure rate of the test product (*p*~T~) versus a pre-defined limit of 70% (see also section [Sample size](#Sec9){ref-type="sec"}). The following null hypothesis was tested: *H*~0,\ prim~: *p*~T~ − *p*~R~ = 0 and *H*~a~: *p*~T~ − *p*~R~ \> 15%, where *p*~R~ is the cure rate of the reference product. The Chi-square test of independence was used to test the null hypothesis. If superiority could not be proven, non-inferiority would be evaluated. Evaluation of non-inferiority is allowed if a non-inferiority margin has been predefined, and no correction were made in terms of multiplicity \[[@CR17]\]. As non-inferiority margin (*δ*), a 7.5% worse cure rate was seen as being clinically not relevant. In the present clinical trial, this analysis was not relevant as results clearly confirmed superiority of the test product.

The Chi-square test for independence was used to compare the cure rate after correction for re-infestation on day 10.

All descriptive and statistical analyses were performed in R version 3.3.4. (R development core team 2017) \[[@CR18]\]. A *p* value of \< 0.05 was considered to be statistical significant. No imputation of missing data was performed.

For the consumer study, continuous data were summarized by their mean, standard deviation (SD), minimum, median, and maximum. Categorical data were summarized by frequencies and percentages. Fizz Sensory Analysis software (Biosystemes Analysis, Couternon, France) was used to perform analysis of variance tests. For time measurement data, a Mann--Whitney test was used. All statistical tests were performed at the 5% level of significance.

Results {#Sec15}
=======

Baseline Data Clinical Trial {#Sec16}
----------------------------

Study data were collected between 7 March 2018 and 30 June 2018. In total, 70 subjects were randomized into two treatment groups, namely, the test product group (32 females, 3 males) and the reference product group (33 females, 2 males). The average age of the participants was 14.2 ± 11.7 (± SD) years, with age ranging from 2 to 50 years. All patients completed the study according to the protocol and were included into the ITT population. A CONSORT flow chart is shown in Fig. [1](#Fig1){ref-type="fig"}. A summary of demographic and clinical characteristics is presented in Table [1](#Tab1){ref-type="table"}.Fig. 1CONSORT flow chart (intention-to-treat population) Table 1Baseline characteristics of participantsBaseline characteristicsTreatment groups (*n* = 35 in each group)Test productReference productAge (years) Average ± SD15.3 ± 12.313.1 ± 10.9 Minimum/median/maximum3/12/502/10/44Sex Male, *n* (%)3 (8.6%)2 (5.7%) Female, *n* (%)32 (91.4%)33 (94.3%)Severity infestation Mild20 (57.1%)20 (57.1%) Moderate8 (22.9%)13 (37.1%) Heavy7 (20%)2 (5.7%)Hair length Short3 (8.6%)4 (11.4%) Medium12 (34.3%)16 (45.7%) Long20 (57.1%)15 (42.9%)Hair curliness Straight8 (22.9%)12 (34.3%) Wavy23 (65.7%)16 (45.7%) Curly4 (11.4%)7 (20.0%)Hair texture Fine4 (11.4%)8 (22.9%) Average28 (80.0%)24 (68.6%) Coarse3 (8.6%)3 (8.6%)Race White35 (100%)35 (100%)Values in table are presented as the average ± standard deviation (SD) or as a number with the percentage in parenthesis

Forty patients (*n* = 20 in both treatment groups) were classified as having a mild infestation of head lice, and 21 patients were assessed as having a moderate infestation (test product group, *n* = 8; reference group, *n* = 13). Compared to the reference product group, more subjects in the test product group suffered from a severe infestation (*n* = 7 vs. *n* = 2, respectively).

Before treatment (visit 0), the average number of adult live lice per subject was 6.3 ± 7.2 (range 0--40). The average number of adult lice and the distribution of nymphs per stage differed slightly between treatment arms.

The number of subjects with short hair was comparable in both groups (test product group *n* = 3; reference product group *n* = 4). With respect to hair length and treatment for head lice infestation, there were more subjects in the reference group (*n* = 16) with medium long hair (shoulder length) treated for head lice than in the test product group (*n* = 12), while in contrast, there were more subjects in the test product group (*n* = 20) with long hair (mid-back) treated for head lice infestation than in the reference group (*n* = 15). Regarding hair curliness and thickness, no important differences were observed between both treatment groups. The data are summarized in Table [1](#Tab1){ref-type="table"}.

Efficacy Results {#Sec17}
----------------

At study end (day 10), only five of 35 subjects were infested in the test product group (cure rate 85.7%). One subject was assessed to be a re-infestation, yielding a cure rate, corrected for re-infestation, of 88.2% (30/34; 95% confidence interval \[CI\] 72.5--96.7%). At study end, 22 patients in the reference product group were not lice-free (cure rate 37.1%). Three subjects were classified as a re-infestation, yielding a cure rate, corrected for re-infestation, of 40.6% (13/32; 95% CI 23.7--59.4%). These data demonstrate that the primary objective (cure rate \> 70%) was only realized for the test product (*p* = 0.023). With a difference between cure rates of 47.6% (95% CI 27.4--67.8%; *χ*^2^: 16.46, *p* \< 0.001), superiority of the test product versus reference product was statistically established.

For all evaluation visits, cure rates were remarkably higher for the test product than for the reference product. Twenty-four hours following initial treatment, 85.7% (30/35) and 60% (21/35) of the subjects were lice-free in the test group and reference group, respectively. Prior to the second treatment, there was a significant advantage of 40% for the test product: 51.4% of the subjects in the test product group were lice-free versus 11.4% in the reference product group.

After the first treatment, the number of subjects who remained lice-free until study end was 57.1% (20/35) in the test product group and 2.9% (1/35) in the reference product group. The results are shown in Table [2](#Tab2){ref-type="table"}.Table 2Cure rates at different evaluation time points, after one and two treatments, respectively, together with the minimum, median, and maximum recorded number of head liceStatisticDay 0 (pre-treatment)Day 0 (post first treatment)Day 1 (post first treatment)Day 7 (pre-second treatment)Day 7 (post second treatment)Day 10 (end of study)Test product group (*n* = 35) Minimum/median/maximum^a^5/7/920/0/160/0/130/0/240/0/20/0/8 Lice-free, *n* (%)--29 (82.9%)30 (85.7%)18 (51.4%)33 (94.3%)30 (85.7%) Lice-free, *n* (%)---corrected----------30/34 (88.2%)Reference product group (*n* = 35) Minimum/median/maximum^a^5/8/540/0/120/0/60/3/140/0/40/1/13 Lice-free, *n* (%)NA20 (57.1%)21 (60%)4 (11.4%)26 (74.3%)13 (37.1%) Lice-free, *n* (%)---corrected13/32 (40.6%)Subjects received the first treatment on day 0 and the and second treatment on day 7^a^Values are the number of subjects infested with head lice

Satisfaction with Esthetical Effect {#Sec18}
-----------------------------------

In the test product group, 91--100% of the subjects responded positively to all questions, whereas no subjects strongly disagreed. Briefly, after the first treatment, 6% of the subjects in this group disagreed with the statement "Hair not too dry"; after the second treatment, only 3% disagreed. Identical results were reported regarding the conditioning effect of the product. Regarding the statements on shininess (Shininess is good) and volume of the hair (Volume is good), 3% of the subjects in the test product group disagreed after the first treatment, whereas none of the subjects in this group disagreed after the second treatment. Finally, after the first treatment, 9% of the subjects disagreed with the statement "Greasiness is normal"; however, at the end of the study, only 3% disagreed.

In the reference product group, 94--100% of the subjects responded positively to all statements, with the exception for that on dryness of the hair. Indeed, 14 and 9% of the subjects in this group disagreed with the statement that the hair does not feel too dry after the first and second treatment, respectively. Furthermore, 3% of the subjects strongly disagreed and 3% disagreed with the statement that the hair feels good after the first treatment; after the second treatment, none of the subjects disagreed.

With respect to the statements on shininess and volume of the hair, and the conditioning effect, the outcomes were comparable in both groups for both treatments. With regards to the statement on greasiness of the hair, 3% or none of the subjects in the reference product group disagreed after the first and second treatment, respectively. The results of this questionnaire are presented in detail in Table [3](#Tab3){ref-type="table"}.Table 3Response to statements on esthetic questionnaire, completed after the first and second treatment, respectivelyParameter/treatmentTest product group at T1Test product group at T2Reference product group at T1Reference product group at T2Hair not too dry94978691Scalp feels pleasant10010010097Hair feels good10010094100Shininess is good9710097100Greasiness is normal919797100Volume is good9710094100Conditioning effect949797100*T1* First treatment,*T2* second treatmentValues in table are presented as the percentage of subjects responding positively

Safety Evaluation {#Sec19}
-----------------

### Local Tolerability {#Sec20}

Local tolerability was assessed during all visits, with the following parameters being assessed: burning, paraesthesia, and pruritus. In the test product group, paraesthesia and burning were not reported. Prior to treatment, pruritus was reported by 77% of the subjects (mild 43%, moderate 23%, severe 11%). At each follow-up visit, the number of subjects reporting pruritus gradually decreased. At study end, only 20% of the subjects reported mild pruritus. Moderate to severe pruritus was not observed. In the reference group, paraesthesia was not reported. Only one subject in this group complained about mild burning before the first treatment, but this did not reoccur. Prior to treatment, pruritus was reported by 69% of the subjects (mild 37%, moderate 23%, severe 9%). At each follow-up visit, the number of subjects reporting pruritus gradually decreased. At study end, 14% reported mild pruritus (no moderate or severe cases). Moderate to severe pruritus was not observed. These results are shown in more detail in Table [4](#Tab4){ref-type="table"}.Table 4Occurrence of adverse events and pruritus during the clinical trial period (10 days)Adverse events and pruritusTreatmentDay 0 (pre-treatment)Day 0 (post first treatment)Day 1 (post first treatment)Day 7 (pre-second treatment)Day 7 (post second treatment)Day 10 (end of study)Adverse events ErythemaTest product333000Reference product000000 Paresthesia and excoriationTest product000000Reference product000000 BurningTest product000000Reference product300000Pruritus NoneTest product22.960.077.174.388.680.0Reference product31.462.985.777.191.485.7 MildTest product42.928.617.125.711.420.0Reference product37.131.414.320.08.614.3 ModerateTest product22.95.75.70.00.00.0Reference product22.95.70.02.90.00.0 SevereTest product11.45.70.00.00.00.0Reference product8.60.00.00.00.00.0Values in table are presented as the percentage of subjects

### Global Tolerability {#Sec21}

At study end, global tolerability was rated as "good" or "very good". The number of subjects in the test product group with the rating "very good" was remarkably higher than that in the reference product group (65.7 vs. 48.6%, respectively).

### Skin Irritations {#Sec22}

Skin erythema was not reported in the test product group. In the reference group, one subject reported mild erythema (24 h post treatment), but this did not reoccur at days 7 and 10, respectively. Scalp excoriation and secondary infections were not reported in both groups.

### Eye Irritations {#Sec23}

For both investigational products, eye tolerability was excellent. None of the subjects suffered from eye redness and irritation over all visits.

### Adverse Events and Serious Adverse Events {#Sec24}

In both treatment groups, no (serious) adverse events were reported.

Consumer Study Outcome {#Sec25}
----------------------

The test product scored significantly better in view of wash-out time. Briefly, an average wash-out time of 17.5 (95% CI 15.1--20.0) min and 11.0 (95% CI 9.3--12.8) min was calculated for the dimethicone reference product and the test product, respectively. This difference was significantly different (*p* \< 0.0001). The shorter wash-out time was also confirmed by the responses to the open comments: 62% of the test subjects indicated spontaneously that the treatment with the dimethicone product was time-consuming.

In case the visual aspect of the hair was not good, consumers were allowed to perform additional washings during the days following treatment. Briefly, a higher number of subjects performed extra washings in the dimethicone reference group (41 vs. 30% with test product), with an average wash-out time of 12.5 and 10.6 min for the dimethicone reference product and test product, respectively. This difference was not significant. Combining the time for initial washing and the extra washing time, an average of 22.6 min was calculated for the dimethicone reference product, whereas treatment time with test product was significantly (*p* \> 0.001) lower (14.2 min). Of note, in the test product group, 22% of the subjects only required one washing, whereas 71% of the subjects positively scored the visual aspect of the hair after two to three washings. In contrast, significantly more washings (up to 7 or more) were required for subjects treated with the dimeticone product. Despite this higher number of washings, the hair was still assessed as significantly greasier by the subjects in this group (39% of the subjects indicated that the hair was too greasy). The feel of the scalp and the feel of the hair scored better with test product but did not significantly differ from the results, obtained with the reference product.

Discussion {#Sec26}
==========

In recent years, insecticide-based products for the treatment of pediculosis capitis have been gradually replaced by alternative products with a physical mode of action, with the primary drivers of this change being growing resistance of head lice to the agents and safety concerns \[[@CR3], [@CR4]\]. Many of these newer products contain silicones (e.g., high-molecular-weight dimethicone) and/or mineral oils. Their physical mode of action relies on suffocation and dehydration of the head lice \[[@CR5], [@CR7], [@CR8]\]. Although these products have been proven to be safe and to have clinical efficacy \[[@CR6], [@CR11], [@CR19], [@CR20]\], they may have a major disadvantage from a cosmetic point of view, silicones in particular. Indeed, because of their lipophilicity, these products may leave a residue on the hair and make it oily and greasy \[[@CR9]\].

Extensive research has revealed that silylated polyols may be interesting alternatives to silicones. Independent in vitro experiments have shown that the test product in this clinical trial, an aqueous dispersion of one of these molecules (Prosil), yields 100% mortality for both lice and nits. Prosil is an interesting molecule because it elicits its effects in an identical manner as dimethicone. Indeed, our microscopic analyses revealed that, following treatment, the respiratory channels of the head lice were completely filled with product in a manner comparable to dimethicone exposure. Furthermore, treated head lice appeared to be highly desiccated (see Fig. [2](#Fig2){ref-type="fig"}). Interestingly, in contrast to silicones, no build up effect on hair strands treated in vitro with the aqueous Prosil dispersion was observed.Fig. 2Assessment of penetration of test products into the respiratory channel of the head lice

From a chemical point of view, Prosil and other silylated polyols differ from silicones in general. Indeed, the latter consists of a siloxane (Si--O--Si) bone structure, whereas the active ingredient only contains organosilicon (Si--O--C) bonds. Both types of molecules are insoluble in polar solvents such as water. However, because of their very low viscosity, silylated polyols can be easily dispersed and stabilized in an aqueous vehicle with medium viscosity. This is not the case for high-molecular-weight silicones, which are very viscous. One could opt for emulsification (oil in water emulsion) to "dissolve" the silylated polyol into the water phase. However, in vitro experimental data have shown that adulticidal activity of the agent was significantly reduced (60% mortality) after emulsification. The most plausible hypothesis for this loss of activity after emulsification is that a permanent oil-in-water emulsion rinses off too easily from the hair and, consequently, the product does not have sufficient time to affect the head lice. This possibility is consistent with the notion that penetration of silicone or oil compounds into the spiracles and respiratory tract is essential to kill head lice and nits. It has recently been shown that water is not able to penetrate the respiratory system of the head lice \[[@CR21]\], a finding which further supports our hypothesis.

Silylated polyalcohols have been observed to self-emulsify in polar solvents over time. To avoid such self-emulsification, a dual chamber packaging was developed. Briefly, the silylated polyol (Prosil) is dissolved in a water-free, lipophilic vehicle, which is stored in the cap. Following activation of the cap, this Prosil phase is released into the aqueous vehicle (containing a viscosity modifier, a perfume, and preservatives). Following shaking, the product can be directly applied to the hair. Interestingly, the formulation remains stable for several weeks without any loss of in vitro activity and without phase separation (probably because of the relatively high viscosity of the product).

The present clinical trial demonstrated that treatment with the test product resulted in a high cure rate of 88.2% at day 10 (corrected for re-infestation), amply exceeding the pre-defined limit of 70%. The latter value lies closely to the highest cure rate (67.7%) reported in a recent clinical trial with a pyrethrum-based pediculicide \[[@CR14]\]. It is important to stress that, at present, this is a rather exceptional outcome. Much lower cure rates have been observed with comparable treatments \[[@CR3], [@CR22]--[@CR27]\], and such lower cure rates are supported by the results obtained with the reference product in the present study. Indeed, over all visits, cure rates were remarkably higher for the test product than for the control at each visit, with a final cure rate of 40.6% (corrected for re-infestation). Furthermore, one single application of the test product was sufficient to keep 57.1% of all patients lice-free until study end, in contrast to 2.9% in the reference product group.

The most logic explanation for the observed results is the growing resistance of head lice towards insecticides. Indeed, over the last decades, cure rates significantly reduced, with levels dropping to 25% \[[@CR28]\]. Knockdown resistance (*kdr*)-type mutations, resulting in nerve insensitivity to pyrethrins and derivatives, are responsible for this phenomenon. A recent study in the USA showed a high percentage of lice (up to 100%) with*kdr*-type mutations in all U.S. states \[[@CR29]\]. The present study was performed in two centers in Florida, which were close to each other. For this reason, a similar resistance profile can be expected in both sites.

In general, insecticide resistance is a worldwide problem and is related to misuse and overexposure. One recent study, performed in Germany, reported an exceptionally high cure rate of 94% following two treatments with a pyrethrum-based lotion. The authors stated that this may be related to the fact that the insecticide-based pediculicides require a prescription and, therefore, people are less exposed \[[@CR11]\]. Despite growing resistance, pyrethrin- and pyrethroid-based products still belong to the first-line, prescription-free treatments available in the USA, although substance-based pediculicides have shown to be superior in view of performance and safety \[[@CR6], [@CR11], [@CR19], [@CR20]\]. As the study was performed in Florida, RID shampoo was used as reference in the present study.

In addition to clinical performance, the esthetic effects of the test product were evaluated during the trial. Subjects highly appreciated the cosmetic effects of the test product following both applications at day 0 and day 7, respectively. Indeed, more than 90% of the test subjects were (very) satisfied with the condition of their hair (shininess, volume, feeling of hair and scalp, dryness, and greasiness). This was further confirmed by the results of the blinded, cross-over consumer study, which showed that a significantly lower rinsing time and number of washings were required to restore the hair in its original form.

With respect to safety, the aqueous lotion consists of ingredients which are approved for use in pharmaceutical and cosmetic products. The active ingredient has a comparable chemical structure to other silylated products which are applied in a variety of cosmetic products. The clinical results showed that the product was well-tolerated, as reflected by the absence of any adverse events (including skin and eye irritation). Similar observations were made for the comparator product.

The limitations of this study include the moderated number of subjects. However, sample size was calculated using the data of earlier clinical trials with silicone- or mineral oil-based pediculicides. Power analysis confirmed that this scale of significant differences between treatments is detectable in a study population of *n* = 50--100. Instead of a pyrethroid-based product, a silicone-based pediculicide might have served as reference, especially in view of the increasing resistance. Also, no subgroup analyses were performed to evaluate the impact of infestation degree, hair characteristics, and other parameters. However, no remarkable differences were found in baseline parameters between both treatment groups. Furthermore, subgroup analyses were not foreseen in the original statistical plan. Subgroup analyses may reveal some trends but because of the relatively low number of subjects, the power of the tests would be insufficient and, therefore, any conclusions may not be correct, statistically seen. Finally, dry combing was used to diagnose a head lice infestation in both treatment groups. This method may be less sensitive compared to wet combing. However, the latter requires the use of a conditioner, which in turn may have an impact on lice and thus on study outcome. For this reason, wet combing was not used as a diagnostic tool.

Conclusions {#Sec27}
===========

In conclusion, the results of the present study demonstrated that treatment with an aqueous dispersion of a silylated polyol resulted in high cure rates compared to a pyrethrum-based, prescription-free pediculicide shampoo. In addition to the high safety profile of the test product, its esthetic effects following application were assessed to be excellent, in contrast to the assessment of silicone-based head lice treatments, showing comparable cure rates but having negative effects on hair quality due to wash-out difficulty and residue build-up.
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